Dear , In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities. OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Targeted Oncology

WuXi AppTec Genetically Engineered Cell Lines for JAK Ba/F3-JAK1 V623A Ba/F3-JAK1 T478S Ba/F3-JAK2 V671F Ba/F3-TYK2 E957D Ba/F3-JAK3 A573V Ba/F3-JAK3 M511I Read More

WuXi AppTec RET-related Tumor Models (1)  TT thyroid and LC-2/ad lung cancer CDX models harboring RET alterations (2)  Ba/F3 cell lines, tested with Cabozatinib, Vandetanib, Lenvatinib, Sunitinib, Regorafenib, Pralsetinib, Ponatinib, Sorafenib, and LOXO-292 in vitro or in vivo: Ba/F3-KIF5B-RET Ba/F3-KIF5B-RET-V804L Ba/F3-KIF5B-RET-V804M Ba/F3-KIF5B-RET-G810S Ba/F3-KIF5B-RET-G810R Ba/F3-CCDC6-RET Ba/F3-CCDC6-RET-V804M Ba/F3-CCDC6-RET-V804L Read More

Translational Oncology

In-Cell Western, enables the high-throughput screening for PROTAC. Read More KPC mouse homograft tumor model, the ideal platform to test combination therapies for PDAC. Read More

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.   Best regards, WuXi AppTec OncoWuXi Team